Erratum: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
出版信息
Am J Respir Crit Care Med. 2019 Mar 15;199(6):809. doi: 10.1164/rccm.v199erratum2.
Abstract
摘要
相似文献
1
Erratum: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Am J Respir Crit Care Med. 2019 Mar 15;199(6):809. doi: 10.1164/rccm.v199erratum2.
2
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.
3
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA. 2003 Oct 1;290(13):1749-56. doi: 10.1001/jama.290.13.1749.
4
Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
J Cyst Fibros. 2010 Jan;9(1):17-23. doi: 10.1016/j.jcf.2009.09.001. Epub 2009 Oct 8.
5
Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
Thorax. 2006 Oct;61(10):895-902. doi: 10.1136/thx.2005.057950. Epub 2006 Jun 29.
6
Synergistic Activity of Berberine with Azithromycin against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung In Vitro and In Vivo.
Cell Physiol Biochem. 2017;42(4):1657-1669. doi: 10.1159/000479411. Epub 2017 Jul 24.
7
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
J Cyst Fibros. 2017 May;16(3):358-366. doi: 10.1016/j.jcf.2016.12.003. Epub 2016 Dec 24.
8
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.
Respir Res. 2006 Oct 25;7(1):134. doi: 10.1186/1465-9921-7-134.
9
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatr Pulmonol. 2007 Jun;42(6):533-41. doi: 10.1002/ppul.20620.
10
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2012 Nov 14;11:CD009528. doi: 10.1002/14651858.CD009528.pub2.
引用本文的文献
1
Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5.
2
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD001021. doi: 10.1002/14651858.CD001021.pub4.
3
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.
Trends Mol Med. 2020 Dec;26(12):1068-1077. doi: 10.1016/j.molmed.2020.08.002. Epub 2020 Aug 28.
本文引用的文献
1
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1177-1187. doi: 10.1164/rccm.201802-0215OC.
Zotero 插件